An investigation of factors associated with depressive symptoms among a sample of regular ecstasy consumers

Neuropsychobiology

Volumn 61, Issue 4, 2010, Pages 215-222

  Matthews, A J ^a   Bruno, R ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Depression; Methylenedioxymethamphetamine; Psychopathology

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS; METHAMPHETAMINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; DEPRESSION; DISEASE ASSOCIATION; DISTRESS SYNDROME; DRUG DEPENDENCE; FEMALE; HEALTH PRACTITIONER; HELP SEEKING BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG ABUSE; PRIORITY JOURNAL; SELF REPORT; STRUCTURED INTERVIEW; SYMPTOMATOLOGY; TOBACCO;

ADOLESCENT; ADULT; CHI-SQUARE DISTRIBUTION; DEPRESSION; FEMALE; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RISK-TAKING; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 77950606215     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000306592     Document Type: Article

References (59)

1. Gouzoulis-Mayfrank E, Daumann J: Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 2006; 101: 348-361. (Pubitemid 43344818)
2. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Balwin RM: Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 -carbomethoxy-3 - (4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998; 44: 1090-1098. (Pubitemid 28547144)
3. Parrott AC, Lasky J: Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 1998; 139: 261-268. (Pubitemid 28439526)
4. Curran V, Travill RA: Mood and cognitive effects of 3,4- methylenedioxymethamphetamine (MDMA, ecstasy): week-end 'high' followed by mid-week low. Addiction 1997; 92: 821-831.
5. Verheyden SL, Hadfield J, Calin T, Curran V: Sub-acute effects of MDMA (3,4-methylenedioxymethamphetamine, 'ecstasy') on mood: evidence of gender differences. Psychopharmacology 2002; 161: 23-31. (Pubitemid 34437965)
6. Verheyden SL, Henry JA, Curran HV: Acute, sub-acute and long term subjective consequences of 'ecstasy' (MDMA) consumption on 430 regular users. Hum Psychopharmacol 2003; 18: 507-517.
7. Topp L, Hando J, Dillon P, Roche A, Solowij N: Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999; 55: 105-115. (Pubitemid 29222009)
8. Falck RS, Carlson RG, Wang J, Siegal HA: Psychiatric disorders and their correlates among young adult MDMA users in Ohio. J Psychoactive Drugs 2006; 38: 19-29.
9. Parrott AC, Milani RM, Parmar R, Turner JJD: Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological symptoms. Psychopharmacology 2001; 159: 77-82. (Pubitemid 34031254)
10. Morgan MJ, McFie L, Fleetwood LH, Robinson JA: Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 2002; 159: 294-303. (Pubitemid 34143378)
11. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H: Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 2002; 68: 195-207. (Pubitemid 35247791)
12. MacInnes N, Handley SL, Harding GFA: Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 2001; 15: 181-186.
13. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C: Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology 2004; 173: 434-439.
14. Gamma A, Buck A, Berthold T, Vollenweider FX: No difference in brain activation during cognitive performance between ecstasy (3,4- methylenedioxymethamphetamine) users and control subjects: a [H 2 15 O]-positron emission tomography study. J Clin Psychopharmacol 2001; 21: 66-71.
15. de Win MML, Reneman L, Reitsma JB, den Heeten GJ, Booij J, van den Brink W: Mood disorders and serotonin transporter density in ecstasy users - The influence of long-term abstention, dose, and gender. Psychopharmacology 2004; 173: 376-382.
16. Hansen KL, Luciana M: Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med 2004; 34: 229-246.
17. Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartorit R, Caccavari R, Delsignore R: Serotonergic function after 3,4- methelenedioxymethamphetamine ('ecstasy') in humans. Int Clin Psychopharmacol 1998; 13: 1-9.
18. Lamers CTJ, Bechara A, Rizzo M, Ramaekers JG: Cognitive function and mood in MDMA/THC users, THC users and nondrug using controls. J Psychopharmacol 2006; 20: 302-311.
19. Thomasius R, Peterson K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A: Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 2003; 167: 85-96.
20. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, Brambilla F: Long-lasting effects of 3,4- methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 2000; 47: 127-136.
21. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E: Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/ longitudinal investigation. Psychopharmacology 2004; 173: 398-404.
22. Dugheiro G, Schifano F, Forza G: Personality dimensions and psychopathological profiles. Hum Psychopharmacol 2001; 16: 635-639.
23. Milani RM, Parrott AC, Turner JD, Fox HC: Gender differences in self-reported anxiety, depression, and somatization among ecstasy/ MDMA polydrug users, alcohol/tobacco users, and nondrug users. Addict Behav 2004; 29: 965-971.
24. Verkes RJ, Gijsman RC, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M, Pennings EJM, de Bruin D, Van de Wijngaart G, Van Gerven JMA, Cohen AF: Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 2001; 153: 196-202.
25. Guillot C, Greenway D: Recreational ecstasy use and depression. J Psychopharmacol 2006; 20: 411-416.
26. Parrott AC, Sisk E, Turner JJD: Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend 2000; 60: 105-110.
27. Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E: Psychological profile of abstinent recreational ecstasy (MDMA) users and significance of concomitant cannabis use. Hum Psychopharmacol 2001; 16: 627-633.
28. Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JI, Yurgelun-Todd D: Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 2004; 75: 135-147.
29. Medina KL, Shear PK: Anxiety, depression, and behavioral symptoms of executive function in ecstasy users: contributions of polydrug use. Drug Alcohol Depend 2007; 87: 303-311.
30. Durdle H, Lundahl LH, Johanson C-E, Tancer M: Major depression: the relative contribution of gender, MDMA, and cannabis use. Depress Anxiety 2008; 25: 241-247.
31. Roiser JP, Sahakian BJ: Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology 2004; 173: 411-417.
32. Guillot C: Is recreational ecstasy (MDMA) use associated with higher levels of depressive symptoms? J Psychoactive Drugs 2007; 39: 31-39.
33. Sumnall HR, Cole JC: Self-reported depressive symptomatology in community samples of polysubstance misusers who report ecstasy use: a meta-analysis. J Psychopharmacol 2005; 19: 84-92.
34. Huizink AC, Ferdinand RF, van der Ende J, Verhulst FC: Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. BMJ 2006; 332: 825-828.
35. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R: MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 1998; 52: 85-90.
36. de Win MML, Schilt T, Reneman L, Vervaeke H, Jager G, Dijkink S, Booij J, van den Brink W: Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study. J Psychopharmacol 2006; 20: 226-235.
37. Alati R, Kinner SA, Hayatbakhsh MR, Al Mamun A, Najman JM, Williams GM: Pathways to ecstasy use in young adults: anxiety, depression or behavioural deviance? Drug Alcohol Depend 2008; 92: 108-115.
38. Roiser JP, Cook LJ, Cooper JD, Rubinsztein DC: Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Am J Psychiatry 2005; 162: 609-612.
39. Verheyden SL, Maidment R, Curran VH: Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. J Psychopharmacol 2003; 17: 371-378.
40. Falck RS, Wang J, Carlson RG, Siegal HA: Prevalence and correlates of current depressive symptomatology among a community sample of MDMA users in Ohio. Addict Behav 2006; 31: 90-101. (Pubitemid 41790451)
41. Australian Bureau of Statistics: 2007 National Survey of Mental Health and Wellbeing: Summary of Results. Canberra, Australian Bureau of Statistics, 2008.
42. Parrott AC, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey AB: Dancing hot on ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users. Hum Psychopharmacol 2006; 21: 285-298. (Pubitemid 44203211)
43. Topp L, Breen C, Kaye S, Darke S: Adapting the Illicit Drug Reporting System (IDRS) methodology to examine the feasibility of monitoring trends in party drug markets. Drug Alcohol Depend 2004; 73: 189-197. (Pubitemid 38071821)
44. Kerlinger FN: Foundations of Behavioral Research. New York, CBS College Publishing, 1986.
45. Matthews A, Bruno R: Tasmanian Trends in Ecstasy and Related Drug Markets 2007: Findings from the Ecstasy and Related Drugs Reporting System (EDRS). Australian Drug Trends Series No 14. Sydney, National Drug and Alcohol Research Centre, University of New South Wales, 2008.
46. Radloff LS: The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
47. Kessler RC, Andrews G, Colpe L, Hiripi E, Mroczek DK, Normand S-LT, Walters EE, Zaslavsky AM: Short screening scales to measure population prevalences and trends in non-specific psychological distress. Psychol Med 2002; 32: 959-976.
48. Weissman MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ: Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977; 106: 203-214. (Pubitemid 8190169)
49. Thomas JL, Jones GN, Scarinci IC, Mehan DJ, Brantley PJ: The utility of the CES-D as a depression screening measure among lowincome women attending primary care clinics. Int J Psychiatry Med 2001; 31: 25-40.
50. Australian Bureau of Statistics: 2004/05 National Health Survey - Summary of Results. Canberra, Australian Bureau of Statistics, 2006.
51. Andrews G, Slade T: Interpreting scores on the Kessler Psychological Distress Scale (K10). Aust NZ J Public Health 2001; 25: 494-497. (Pubitemid 34044202)
52. Topp L, Mattick RP: Choosing a cut-off on the severity of dependence scale (SDS) for amphetamine users. Addiction 1997; 92: 839-845. (Pubitemid 27326237)
53. Dubini A, Mannheimer R, Pancheri P: Depression in the community: results of the first Italian survey. Int Clin Psychopharmacol 2001; 16: 49-53. (Pubitemid 32042841)
54. Vanheusden K, van der Ende J, Mulder CL, van Lenthe FJ, Verhulst FC, Mackenbach JP: Beliefs about mental health problems and help-seeking behavior in Dutch young adults. Soc Psychiatry Psychiatr Epidemiol 2009; 44: 239-246.
55. Shean G, Baldwin G: Sensitivity and specificity of depression questionnaires in a college- age sample. J Genet Psychol 2008; 169: 281-283.
56. Vazquez FL, Blanco V: Symptoms of depression and related factors among Spanish university students. Psychol Rep 2006; 99: 583-590. (Pubitemid 44831824)
57. Lee A, Browne MO: Subjective well-being, sociodemographic factors, mental and physical health of rural residents. Aust J Rural Health 2008; 16: 290-296.
58. Taylor R, Page A, Morrell S, Carter G, Harrison J: Socio-economic differentials in mental disorder and suicide attempts in Australia. Br J Psychiatry 2004; 185: 486-493. (Pubitemid 39643284)
59. Degenhardt L, Hall W, Lynskey M: Exploring the association between cannabis use and depression. Addiction 2003; 98: 1493-1504.